Biodexa Pharmaceuticals Plc (BDRX) carries a DilutionWatch risk score of 66/100 — placing it in the HIGH tier. This score is calculated from real SEC filing data including shelf registration capacity, ATM program activity, warrant overhang, cash runway, and historical dilution patterns.
A score of 66/100 indicates multiple active dilution risk factors. Investors should monitor SEC filings closely and consider position sizing carefully.
The DilutionWatch composite score weighs five key factors pulled directly from SEC EDGAR filings. Here's what's contributing to BDRX's score of 66/100:
Companies file S-3 "shelf" registrations to pre-authorize future securities offerings. The size of registered but unissued shares relative to market cap is one of the strongest predictors of future dilution. DilutionWatch tracks active shelf capacity for BDRX in real time — any 424B5 prospectus supplement filed against the shelf signals an imminent offering.
At-The-Market (ATM) programs allow companies to drip-sell shares into the open market daily without a formal offering announcement. If BDRX has an active ATM program (identified by 424B3 filings referencing a "Sales Agreement"), shares are being continuously issued. This creates persistent downward pressure with no clear end date.
Outstanding warrants and convertible notes represent shares that haven't been issued yet but will be — often at a discount to market price. A high warrant coverage ratio (warrants outstanding as a % of current share count) caps any rally and guarantees future dilution when the instruments are exercised or converted.
How long can BDRX operate without raising new capital? DilutionWatch estimates cash runway from the most recent 10-Q balance sheet and quarterly burn rate. Companies in the Biotechnology / Healthcare space with under 6 months of runway almost always raise capital through equity — meaning more shares.
The share count history doesn't lie. DilutionWatch tracks how many times BDRX has increased shares outstanding, whether it has a reverse split history, and the rate of share count growth over 1, 2, and 3 years. Serial diluters almost always dilute again.
Biodexa Pharmaceuticals Plc (BDRX) operates in the biotechnology and healthcare sector — one of the highest-dilution sectors in public markets. Biotech companies typically have no revenue, burn cash on clinical trials, and must return to capital markets repeatedly to fund operations.
For BDRX investors, the core dilution risk question is: how much runway does the company have before it needs to raise again? DilutionWatch tracks BDRX's cash position, quarterly burn rate, and active shelf capacity to model this in real time.
Biotech stocks often spike sharply on positive data — then see immediate dilutive offerings as management locks in capital at favorable prices. DilutionWatch alerts fire on these opportunistic offerings within minutes.
The BDRX score updates automatically as new SEC filings appear — typically within 60 seconds of EDGAR publication. The score you see on the BDRX live page reflects the most current filing data.
Given BDRX's high risk score, the filings most worth watching are:
DilutionWatch monitors BDRX and 10,000+ other tickers with 60-second EDGAR polling. Add BDRX to your watchlist and get alerted the moment a dilution filing appears — before the stock reprices.
Set Up BDRX Alert Free →A score of 66 places BDRX in the high risk tier of DilutionWatch's rating system. It means multiple risk factors are present — not just one red flag. Investors should use this as a signal to monitor the stock and understand the specific dilution mechanisms that are driving the score.
The score updates automatically when new SEC filings appear. DilutionWatch polls EDGAR every 60 seconds. Most filings appear in the DilutionWatch database within 1-3 minutes of being published by the SEC.
All BDRX filings are available at SEC EDGAR. DilutionWatch provides parsed alerts and risk scoring on top of the raw filings.